Jiangsu Nhwa Pharmaceutical vs Sichuan Kelun Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Jiangsu Nhwa Pharmaceutical Co Ltd (002262.CS)

Q3 202617 Aug – 29 Sep 2026

▲2

Nhwa's H1 profit rises 5.7% on fast-growing neurology drugs; pipeline and AI bets advance

First-half profit and revenue grew, led by neurology products Nhwa's first-half net profit rose 5.7% to 741 million yuan and revenue rose 6.9% to 3.218 billion yuan. Neurology product sales jumped 33.7%, the fastest-growing core segment, while anesthetics and psychiatric drugs also grew. Steady profit growth supports the share price.
The half-year results are the period's main hard financial news and show the core business still growing.
Cash flow and margins weakened even as profit rose Operating cash flow fell 43.3% to 280 million yuan, and gross margin slipped 1.38 points to 73.86%. Profit still grew, but weaker cash generation and margins are a real counterweight that can cap gains or make investors cautious.
It is the main negative in the results and gives a fair, balanced picture of the period.
New drug pipeline advances, including a new clinical approval Nhwa's Class 1 drug NH302 injection won clinical trial approval for treating acute pain. Its innovative drug NH600001 has been submitted for marketing approval, and schizophrenia drug NHL35700 entered Phase III. A richer pipeline raises hopes for future growth.
Pipeline progress is a key long-term value driver and includes a genuinely new approval this period.
AI mental-health unit raises 262 million yuan, diluting Nhwa slightly Investee Haoxinqing will raise 262 million yuan from seven new investors to fund AI psychological companion robots and digital mental-health tools. Nhwa waived its right to subscribe, so its stake falls from 19.10% to 18.04%, but it stays the largest shareholder.
It is the period's main corporate action and shows both an AI growth bet and mild dilution.

September 202617 Aug – 29 Sep 2026

▲2

Nhwa's H1 profit rises 5.7% on fast-growing neurology drugs; pipeline and AI bets advance

First-half profit and revenue grew, led by neurology products Nhwa's first-half net profit rose 5.7% to 741 million yuan and revenue rose 6.9% to 3.218 billion yuan. Neurology product sales jumped 33.7%, the fastest-growing core segment, while anesthetics and psychiatric drugs also grew. Steady profit growth supports the share price.
The half-year results are the period's main hard financial news and show the core business still growing.
Cash flow and margins weakened even as profit rose Operating cash flow fell 43.3% to 280 million yuan, and gross margin slipped 1.38 points to 73.86%. Profit still grew, but weaker cash generation and margins are a real counterweight that can cap gains or make investors cautious.
It is the main negative in the results and gives a fair, balanced picture of the period.
New drug pipeline advances, including a new clinical approval Nhwa's Class 1 drug NH302 injection won clinical trial approval for treating acute pain. Its innovative drug NH600001 has been submitted for marketing approval, and schizophrenia drug NHL35700 entered Phase III. A richer pipeline raises hopes for future growth.
Pipeline progress is a key long-term value driver and includes a genuinely new approval this period.
AI mental-health unit raises 262 million yuan, diluting Nhwa slightly Investee Haoxinqing will raise 262 million yuan from seven new investors to fund AI psychological companion robots and digital mental-health tools. Nhwa waived its right to subscribe, so its stake falls from 19.10% to 18.04%, but it stays the largest shareholder.
It is the period's main corporate action and shows both an AI growth bet and mild dilution.

Latest17 Aug – 29 Sep 2026

▲2

Nhwa's H1 profit rises 5.7% on fast-growing neurology drugs; pipeline and AI bets advance

First-half profit and revenue grew, led by neurology products Nhwa's first-half net profit rose 5.7% to 741 million yuan and revenue rose 6.9% to 3.218 billion yuan. Neurology product sales jumped 33.7%, the fastest-growing core segment, while anesthetics and psychiatric drugs also grew. Steady profit growth supports the share price.
The half-year results are the period's main hard financial news and show the core business still growing.
Cash flow and margins weakened even as profit rose Operating cash flow fell 43.3% to 280 million yuan, and gross margin slipped 1.38 points to 73.86%. Profit still grew, but weaker cash generation and margins are a real counterweight that can cap gains or make investors cautious.
It is the main negative in the results and gives a fair, balanced picture of the period.
New drug pipeline advances, including a new clinical approval Nhwa's Class 1 drug NH302 injection won clinical trial approval for treating acute pain. Its innovative drug NH600001 has been submitted for marketing approval, and schizophrenia drug NHL35700 entered Phase III. A richer pipeline raises hopes for future growth.
Pipeline progress is a key long-term value driver and includes a genuinely new approval this period.
AI mental-health unit raises 262 million yuan, diluting Nhwa slightly Investee Haoxinqing will raise 262 million yuan from seven new investors to fund AI psychological companion robots and digital mental-health tools. Nhwa waived its right to subscribe, so its stake falls from 19.10% to 18.04%, but it stays the largest shareholder.
It is the period's main corporate action and shows both an AI growth bet and mild dilution.

Sichuan Kelun Pharmaceutical Co Ltd (002422.CS)

Q3 202627 Jul – 8 Oct 2026

▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.
Shows pipeline progress that can lift long-term growth expectations for the stock.
National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.
Directly increases expected product demand and market share, a core earnings driver.
Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.
Earnings growth and shareholder returns are the main fundamental supports for the share price.
Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.
These are the main counterweights that could hurt sentiment and valuation.

September 202627 Jul – 8 Oct 2026

▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.
Shows pipeline progress that can lift long-term growth expectations for the stock.
National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.
Directly increases expected product demand and market share, a core earnings driver.
Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.
Earnings growth and shareholder returns are the main fundamental supports for the share price.
Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.
These are the main counterweights that could hurt sentiment and valuation.

Latest27 Jul – 8 Oct 2026

▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.
Shows pipeline progress that can lift long-term growth expectations for the stock.
National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.
Directly increases expected product demand and market share, a core earnings driver.
Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.
Earnings growth and shareholder returns are the main fundamental supports for the share price.
Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.
These are the main counterweights that could hurt sentiment and valuation.